Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02217709CT.gov Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | — | Completed | — | — | — |
NCT01253642CT.gov Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Phenelzine (this asset) | University of Southern California | P2 | B · 57 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Prednisone | Mayo Clinic | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Phenelzine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 57 |
| Depressive Disorder | — | P4 | B · 57 |
| Major Depressive Disorder | — | P4 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Phenelzine in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/phenelzine-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →